Johnson & Johnson-backed cancer drug developer Aduro has filed for an initial public offering, following a $51.4m series D round in January.
Aduro Biotech, a US-based developer of treatments for pancreatic cancer backed by healthcare products manufacturer Johnson & Johnson, filed for an initial public offering on Wednesday that could raise up to $86m.
The company originally filed confidentially in December 2014.
Founded in 2000, Aduro is developing vaccine technology to combat metastatic pancreatic cancer. Its lead product candidate, CRS-207, is currently in Phase 2b clinical trials, and the company is advancing a pipeline of other candidates.
Aduro has raised approximately $160m…
